Zacks Research Has Bullish Estimate for APLS FY2025 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at Zacks Research increased their FY2025 EPS estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, September 16th. Zacks Research analyst Team now expects that the company will post earnings per share of ($1.81) for the year, up from their previous estimate of ($1.82). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.52) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.36) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The firm had revenue of $171.39 million during the quarter, compared to analyst estimates of $187.91 million. During the same period last year, the business earned ($0.30) earnings per share. The business’s revenue was down 10.6% on a year-over-year basis.

Several other equities analysts have also issued reports on APLS. Wells Fargo & Company lifted their target price on shares of Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an “equal weight” rating in a report on Monday, June 2nd. Morgan Stanley boosted their price objective on shares of Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 2nd. Wall Street Zen upgraded shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Apellis Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, August 4th. Finally, Robert W. Baird boosted their price objective on shares of Apellis Pharmaceuticals from $47.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.12.

Apellis Pharmaceuticals Price Performance

APLS stock opened at $23.38 on Thursday. The firm has a 50 day moving average price of $24.20 and a 200-day moving average price of $21.28. Apellis Pharmaceuticals has a 52-week low of $16.10 and a 52-week high of $37.83. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of -12.85 and a beta of 0.73. The company has a debt-to-equity ratio of 2.90, a quick ratio of 3.16 and a current ratio of 3.77.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in APLS. Vanguard Group Inc. grew its position in shares of Apellis Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 10,130,356 shares of the company’s stock valued at $221,551,000 after acquiring an additional 84,331 shares during the period. AQR Capital Management LLC grew its position in shares of Apellis Pharmaceuticals by 46.6% during the 2nd quarter. AQR Capital Management LLC now owns 5,976,414 shares of the company’s stock valued at $103,452,000 after acquiring an additional 1,898,995 shares during the period. Marshall Wace LLP grew its position in shares of Apellis Pharmaceuticals by 11,373.8% during the 2nd quarter. Marshall Wace LLP now owns 2,704,837 shares of the company’s stock valued at $46,821,000 after acquiring an additional 2,681,263 shares during the period. Jennison Associates LLC grew its position in shares of Apellis Pharmaceuticals by 7.4% during the 2nd quarter. Jennison Associates LLC now owns 2,661,823 shares of the company’s stock valued at $46,076,000 after acquiring an additional 184,292 shares during the period. Finally, Norges Bank bought a new stake in shares of Apellis Pharmaceuticals during the 2nd quarter valued at $40,977,000. Institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 49,963 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $28.39, for a total value of $1,418,449.57. Following the completion of the sale, the chief executive officer owned 307,946 shares of the company’s stock, valued at approximately $8,742,586.94. The trade was a 13.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel David O. Watson sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $24.34, for a total transaction of $121,700.00. Following the completion of the sale, the general counsel directly owned 118,730 shares of the company’s stock, valued at approximately $2,889,888.20. This trade represents a 4.04% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 399,827 shares of company stock valued at $9,943,384. 6.50% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).